Combination hormonal therapy: a reassessment within advanced prostate cancer (Q35886568)

10 August 2017

1 reference

title

Combination hormonal therapy: a reassessment within advanced prostate cancer (English)

1 reference

10 August 2017

Moul JW

1

1 reference

PubMed ID

15365575

10 August 2017

Chodak G

series ordinal

2

1 reference

10 August 2017

1 September 2004

1 reference

Prostate Cancer and Prostatic Diseases

10 August 2017

1 reference

10 August 2017

7 Suppl 1

1 reference

10 August 2017

S2-7

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500741

10 August 2017

0 references

cites work

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Design and analysis of non-inferiority mortality trials in oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

A re-assessment of the role of combined androgen blockade for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

An evaluation of bicalutamide in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

21 January 2018

Flutamide Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Combined androgen blockade: an optimal therapy for minimally advanced prostate cancer?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Combined androgen blockade in prostate cancer: meta-analyses and associated issues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Interstitial pneumonitis following bicalutamide treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500741

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500741

1 reference

10 August 2017

1 reference

PubMed ID

15365575